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Many pharmacogenetic studies fail to yield any statistically significant associa-
tions. Such negative findings may be due to the absence of, or inadequate
statistical power to test for, an effect at the genetic variants tested. In many
instances, sample sizes are small, making it unclear how to interpret the absence
of statistically significant findings. We demonstrate that the amount of informa-
tion that can be drawn from a negative study is improved by incorporating
statistical power and the added context of well-validated pharmacogenetic effects
into the interpretation process. This approach permits clearer inferences to be
made about the possible range of genetic effects that may be present in, or are
likely absent from, small drug studies.
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Many pharmacogenetic studies result
in negative findings, such that no
statistically significant associations
are observed between genetic variants
and phenotype. Reasons for negative
findings include absence of a genetic
effect, not measuring the causal var-
iant, or low power due to small sample
sizes, small effect sizes or genetic
heterogeneity.
1 Interpretation guide-
lines for negative findings are available
for classical clinical studies.
2,3 How-
ever, pharmacogenetic studies often
differ from other clinical studies by
being very exploratory and investigat-
ing a large number of variants.
4 Never-
theless, we now have a number
of well-validated pharmacogenetic
effects, which allow us to assess the
informativeness of a negative finding
by assessing power to detect associa-
tions with these validated effects. We
propose a strategy for interpretation
that supports stronger inferences
about the possible range of genetic
effects that may be present, but un-
observed, in a study. We illustrate our
approach by evaluating the negative
findings from three studies.
A central question to address is what
additional information, aside from fail-
ure to reject the null hypothesis of no
association between measured geno-
types and phenotype, can be drawn
from a negative finding. Most genetic
studies base their inference primarily on
P-values. Such an approach is not with-
out disadvantages. Criticisms of using
P-values for inference include the in-
ability to judge the relative probabilities
of the null or alternative hypotheses
given the data, the abrupt and false
dichotomy between significant and not
significant, the impact of sample size on
the interpretation, and the dependence
of power on minor allele frequency.
5,6
One way to address these shortcomings
is to adopt a Bayesian approach, such as
estimating the posterior probability of
association.
6 Other useful tools include
confidence intervals for effect size and
the careful investigation of power to
determine what effect sizes could be
detected from the study at hand and,
thus, what effects sizes can be confi-
dently excluded.
Additional inference can be drawn
from negative studies by placing upon
the graph points corresponding to
well-known pharmacogenetic effect
sizes associated with various medicines
and clinical outcomes
4,7–14 (Supple-
mentary Tables 1 and 2) over the
power curves for selected levels (see
Statistical Methods in Supplementary
Material). We can use power levels to
differentiate the kind of effects we are
likely to miss (e.g., power of 5%), have
a reasonable chance of missing (50%)
and are very unlikely to miss (95%). By
adding the 95% simultaneous confi-
dence intervals of effects estimated for
each variant tested, we can assess the
range of plausible effects given the
observed data.
We demonstrate this power-based
approach to interpretation using three
examples selected from recent studies
we have conducted. The first example
is based on a pharmacogenetic study of
pazopanib-related liver enzyme eleva-
tion, consisting of the analysis of 48
cases and 94 controls.
15 For the given
sample size, the effect sizes for almost
all well-established adverse drug reac-
tions lie above the 95% power curve
(Figure 1a). Consequently, rejection
would have been very likely if similar
effects were present among the genetic
variants tested. The second example
illustrates our method for severe cuta-
neous adverse reactions in patients
who received lamotrigine,
11 consisting
of 10 cases and 43 controls (Figure 1b).
These power curves indicate that only
the largest reported effects could be
confidently ruled out. The third exam-
ple is modeled after a pharmacokinetic
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129 subjects (Figure 2). As in the first
example, we can confidently exclude
the presence of effect sizes observed for
most large pharmacokinetic effects. We
also applied the Bayesian posterior
probability of association to these
studies (data not shown). We did not
find this measure to provide much
additional insight beyond the confi-
dence intervals.
The combination of power curves,
observed effects and examples of well-
known effects can help researchers to
draw meaningful information about
potential pharmacogenetic effects
from otherwise ambiguous results.
Most of this information is derived
from the magnitude of the effects that
are likely to be rejected by the study.
As expected, the information in a
negative study depends strongly on
the sample size. For larger negative
studies, we can exclude a large part of
the effect size space, including most
well-known effect sizes with demon-
strated clinical utility. Such negative
studies are informative, because they
confidently exclude the existence of
large effects at the measured variants.
On the other hand, for a small study,
we might have sufficient power to
exclude only the largest possible effect
sizes, and little power to exclude most
known effects. Consequently, the in-
formation gained from such a negative
finding is low, and researchers should
be cautious drawing any conclusions.
Figure 2 Power at a type I error of 510
4 for a pharmacogenetic investigation of pharma-
cokinetic variation. Effect size measure is standardized mean difference, described in Online
Methods. Drug abbreviations are as follows: Ato, Atomoxetine; Clo, Clopidogrel; Des, Desipr-
amine; Mer, Mercaptopurine; Ome, Omeprazole; Phe, Phenytoin; War, Warfarin. See the legend
to Figure 1 for further details.
Figure 1 Power at a type I error of 510
4
(simultaneous testing of 100 variants) for
pazopanib (a) and lamotrigine (b) studies
investigating whether selected human leuko-
cyte antigen genotypes are associated with
adverse drug reactions. Data-derived features
presented in the plot are the estimated odds
ratios (OR; blue horizontal segments) for
individual variants, their 95% simultaneous
confidence intervals (green) and red power
curves corresponding to 95% (solid), 50%
(dashed) and 5% (dash-dotted) power. ORs
for drugs with well-known pharmacogenetic
effects
4,11–14 are plotted as magenta star
characters with the following abbreviations:
Aba, Abacavir; Aug Augmentin; All, Allopur-
inol; Car, Carbamazepine; Flu, Flucloxacillin;
Iri, Irinotecan; Iso, Isoniazid; Lap, Lapatinib;
Lum, Lumiracoxib; Mer, Mercaptopurine; Tic,
Ticlopidine; Tra, Tranilast.
Negative findings in small pharmacogenetic studies
S-A Bacanu et al
94
The Pharmacogenomics JournalAlthough for illustration purposes we
used the power curves method retro-
spectively, this method would provide
maximal benefit when used in the
experiment design stage. At this stage,
the power curves can be produced to
inform the researchers about the kinds
of effects that could be detected and
rejected in a proposed study. On the
basis of estimated power for well-
known effects, scientists will be better
able to predict the possible conse-
quences of the proposed genetic study.
Conflict of interest
The authors declare no conflict of
interest.
Correspondence: Dr S-A Bacanu,
Department of Psychiatry, Virginia
Commonwealth University, Virginia
Biotechnology Park, 800 E. Leigh Street.
Room 1-112B, Richmond, VA 23219, USA.
E-mail: sabacanu@vcu.edu
References
1 McClellan J, King MC. Genomic analysis of
mental illness: a changing landscape. JAMA
2010; 303: 2523–2524.
2 Freedman KB, Bernstein J. Sample size and
statistical power in clinical orthopaedic
research. J Bone Joint Surg Am 1999; 81:
1454–1460.
3 Motulsky H. Chapter 12. Interpreting non-
significant P values. Oxford University Press:
Oxford, 1995.
4 Nelson MR, Bacanu SA, Mosteller M, Li L,
Bowman CE, Roses AD et al. Genome-wide
approaches to identify pharmacogenetic
contributions to adverse drug reactions.
Pharmacogenomics J 2008; 9: 23–33.
5 Spiegelhalter DJ, Abrams KR, Myles JP.
Comparison of Alternative Approaches to
Inference. Bayesian Approaches to Clinical
Trials and Health-Care Evaluation. John Wiley
& Sons, Ltd: Chichester, UK, 2004.
6 Wakefield J. A Bayesian measure of the
probability of false discovery in genetic
epidemiology studies. Am J Hum Genet
2007; 81: 208–227.
7 Desta Z, Zhao X, Shin JG, Flockhart DA.
Clinical significance of the cytochrome P450
2C19 genetic polymorphism. Clin Pharma-
cokinet 2002; 41: 913–958.
8 Furman KD, Grimm DR, Mueller T,
Holley-Shanks RR, Bertz RJ, Williams LA
et al. Impact of CYP2D6 intermediate meta-
bolizer alleles on single-dose desipramine
pharmacokinetics. Pharmacogenetics 2004;
14: 279–284.
9 Furuta T, Ohashi K, Kosuge K, Zhao XJ,
Takashima M, Kimura M et al. CYP2C19
genotype status and effect of omeprazole on
intragastric pH in humans. Clin Pharmacol
Ther 1999; 65: 552–561.
10 Huang YS, Chern HD, Su WJ, Wu JC, Chang
SC, Chiang CH. Cytochrome P450 2E1
genotype and the susceptibility to antitu-
berculosis drug-induced hepatitis. Hepatol-
ogy 2003; 37: 924–930.
11 Kazeem GR, Cox C, Aponte J, Messenheimer
J, Brazell C, Nelsen AC et al. High-resolution
HLA genotyping and severe cutaneous
adverse reactions in lamotrigine-treated
patients. Pharmacogenet Genomics 2009;
19: 661–665.
12 Sauer JM, Ring BJ, Witcher JW. Clinical
pharmacokinetics of atomoxetine. Clin Phar-
macokinet 2005; 44: 571–590.
13 Uno T, Sugimoto K, Sugawara K, Tateishi T.
The effect of CYP2C19 genotypes on the
pharmacokinetics of warfarin enantiomers.
J Clin Pharm Ther 2008; 33: 67–73.
14 Varenhorst C, James S, Erlinge D, Brandt JT,
Braun OO, Man M et al. Genetic variation of
CYP2C19 affects both pharmacokinetic and
pharmacodynamic responses to clopidogrel
but not prasugrel in aspirin-treated patients
with coronary artery disease. Eur Heart J
2009; 30: 1744–1752.
15 Xu CF, Reck BH, Goodman VL, Xue Z,
Huang L, Barnes MR et al. Association of
the hemochromatosis gene with pazopanib-
induced transaminase elevation in renal cell
carcinoma. J Hepatol 2011; 54: 1237–1243.
This work is licensed
under the Creative Com-
monsAttribution-NonCommercial-
No Derivative Works 3.0 Unported
License. To view a copy of this
license, visit http://creativecom
mons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.com/tpj)
Negative findings in small pharmacogenetic studies
S-A Bacanu et al
95
The Pharmacogenomics Journal